Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump

Market Focus11-12 22:23

On November 12, Recursion Pharmaceuticals, Inc. fell 5.01% in Pre-Market Trading, trading at $3.4195 per share, with turnover of $1.0612 million.

The most direct backdrop is a market reassessment following the prior session’s REC-4881-driven advance, as investors continue to evaluate the program’s planned registrational trial path and the scope for valuation recovery.

Recent company updates showed REC-4881 Phase 2 data indicating meaningful reductions in polyp burden in familial adenomatous polyposis patients, with a relatively clean safety profile supporting a registrational study. Separately, Recursion Pharmaceuticals, Inc. reported third-quarter revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, and the company also appointed industry veteran Fred Hassan as chair of the board. Even with those developments, the latest price move suggests attention has shifted from the initial data reaction to execution risks around later-stage development and commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151769584?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-12 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151769584","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump","media":"Market Focus","content":"<p><p>On November 12, Recursion Pharmaceuticals, Inc. fell 5.01% in Pre-Market Trading, trading at $3.4195 per share, with turnover of $1.0612 million.</p><p>The most direct backdrop is a market reassessment following the prior session’s REC-4881-driven advance, as investors continue to evaluate the program’s planned registrational trial path and the scope for valuation recovery.</p><p>Recent company updates showed REC-4881 Phase 2 data indicating meaningful reductions in polyp burden in familial adenomatous polyposis patients, with a relatively clean safety profile supporting a registrational study. Separately, Recursion Pharmaceuticals, Inc. reported third-quarter revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, and the company also appointed industry veteran Fred Hassan as chair of the board. Even with those developments, the latest price move suggests attention has shifted from the initial data reaction to execution risks around later-stage development and commercialization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-12 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 12, Recursion Pharmaceuticals, Inc. fell 5.01% in Pre-Market Trading, trading at $3.4195 per share, with turnover of $1.0612 million.</p><p>The most direct backdrop is a market reassessment following the prior session’s REC-4881-driven advance, as investors continue to evaluate the program’s planned registrational trial path and the scope for valuation recovery.</p><p>Recent company updates showed REC-4881 Phase 2 data indicating meaningful reductions in polyp burden in familial adenomatous polyposis patients, with a relatively clean safety profile supporting a registrational study. Separately, Recursion Pharmaceuticals, Inc. reported third-quarter revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, and the company also appointed industry veteran Fred Hassan as chair of the board. Even with those developments, the latest price move suggests attention has shifted from the initial data reaction to execution risks around later-stage development and commercialization.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1151769584","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151769584","pubTimestamp":1794493416,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 12, Recursion Pharmaceuticals, Inc. fell 5.01% in Pre-Market Trading, trading at $3.4195 per share, with turnover of $1.0612 million.The most direct backdrop is a market reassessment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"走势警报|Recursion Pharmaceuticals, Inc. 盘前交易中下跌 5.01%，市场在之前数据驱动的跳涨后重新评估 REC-4881 注册路径","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"On November 12, Recursion Pharmaceuticals, Inc. fell 5.01% in Pre-Market Trading, trading at $3.4195 per share, with turnover of $1.0612 million.The most direct backdrop is a market reassessment following the prior session’s REC-4881-driven advance, as investors continue to evaluate the program’s planned registrational trial path and the scope for valuation recovery.Recent company updates showed REC-4881 Phase 2 data indicating meaningful reductions in polyp burden in familial adenomatous polyposis patients, with a relatively clean safety profile supporting a registrational study. Separately, Recursion Pharmaceuticals, Inc. reported third-quarter revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22, and the company also appointed industry veteran Fred Hassan as chair of the board. Even with those developments, the latest price move suggests attention has shifted from the initial data reaction to execution risks around later-stage development and commercialization.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151769584","isCrawlerRequest":true}